Kalshi to Offer Bets on Clinical Trials and FDA Decisions

• Investors can bet on specific drugs rather than entire companies, with contracts based on named public documents like ClinicalTrials.gov endpoints or FDA approval letters
• Launch includes over a dozen FDA decisions, such as approval odds for Gilead's cancer drug anito-cel and Summit Therapeutics' lung cancer drug ivonescimab
• The platform requires employment verification for traders and prohibits trading by anyone holding material nonpublic information to prevent insider trading

Summary

Key Development:

Prediction market platform Kalshi announced Thursday it will launch betting markets on clinical trial outcomes and FDA regulatory decisions, partnering with trial-monitoring firm AppliedXL. This marks the first time drug-development odds will be publicly available for trading.

Market Structure:

• Initial pilot program focuses exclusively on late-stage clinical trials
• Contracts listed only after trials complete enrollment
• Each contract based on specific public documents (ClinicalTrials.gov endpoints, FDA approval letters, advisory committee votes)
• AppliedXL defines evaluation criteria before trading begins

Available Contracts at Launch:

The platform will offer betting on over a dozen FDA decisions, including:

• Gilead's experimental cancer drug anito-cel
• Summit Therapeutics' lung cancer treatment ivonescimab
• AriBio's early Alzheimer's disease drug trial outcomes

Regulatory Safeguards:

• Employment verification required for all traders
• Strict prohibition on trading by individuals with material nonpublic information

Market Implications:

This innovation allows investors to take positions on individual drug candidates rather than entire pharmaceutical companies, potentially creating more granular investment opportunities in the biotech sector. The platform could increase price discovery and transparency around drug development probabilities.

Background:

Launched in 2021, Kalshi currently offers prediction markets on sports, elections, and weather events. The expansion into pharmaceutical outcomes represents a significant move into healthcare sector speculation.

The development could impact how investors assess biotech risk and create new hedging opportunities for pharmaceutical stakeholders.